Connor, Clark & Lunn Investment Management (CC&L)
MDGL icon

Connor, Clark & Lunn Investment Management (CC&L)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Sell
1,782
-26,155
-94% -$13.4M ﹤0.01% 1208
2026
Q1 		$14.6M Sell
27,937
-30,358
-52% -$14.5M 0.03% 390
2025
Q4 		$33.9M Sell
58,295
-27,478
-32% -$14M 0.09% 188
2025
Q3 		$39.3M Sell
85,773
-14,322
-14% -$5.34M 0.12% 157
2025
Q2 		$30.3M Sell
100,095
-2,265
-2% -$675K 0.11% 171
2025
Q1 		$33.9M Sell
102,360
-928
-0.9% -$305K 0.15% 120
2024
Q4 		$31.9M Buy
103,288
+31,205
+43% +$8.78M 0.14% 116
2024
Q3 		$15.3M Sell
72,083
-10,979
-13% -$2.81M 0.07% 203
2024
Q2 		$23.3M Sell
83,062
-10,535
-11% -$2.51M 0.1% 168
2024
Q1 		$25M Buy
93,597
+39,490
+73% +$9.3M 0.11% 170
2023
Q4 		$12.5M Buy
54,107
+2,421
+5% +$424K 0.06% 246
2023
Q3 		$7.55M Sell
51,686
-14,075
-21% -$2.65M 0.04% 297
2023
Q2 		$15.2M Sell
65,761
-2,903
-4% -$786K 0.08% 196
2023
Q1 		$16.6M Buy
68,664
+8,257
+14% +$2.25M 0.09% 178
2022
Q4 		$17.5M Buy
60,407
+35,418
+142% +$3.46M 0.1% 158
2022
Q3 		$1.62M Buy
24,989
+18,264
+272% +$1.27M 0.01% 538
2022
Q2 		$481K Buy
6,725
+3,376
+101% +$248K ﹤0.01% 791
2022
Q1 		$329K Sell
3,349
-1,096
-25% -$92.4K ﹤0.01% 856
2021
Q4 		$377K Buy
4,445
+1,871
+73% +$154K ﹤0.01% 858
2021
Q3 		$205K Buy
+2,574
New +$222K ﹤0.01% 944
2019
Q1 		– Sell
-6,650
Closed -$750K – 996
2018
Q4 		$750K Sell
6,650
-1,800
-21% -$279K 0.01% 613
2018
Q3 		$1.81M Buy
+8,450
New +$2.12M 0.01% 456
2016
Q3 		– Sell
-10,749
Closed -$98K – 887
2016
Q2 		$98K Hold
10,749
– – ﹤0.01% 804
2016
Q1 		$90K Hold
10,749
– – ﹤0.01% 772
2015
Q4 		$132K Buy
10,749
+4,018
+60% +$110K ﹤0.01% 734
2015
Q3 		$410K Buy
6,731
+3,725
+124% +$269K ﹤0.01% 555
2015
Q2 		$235K Sell
3,006
-425
-12% -$35.7K ﹤0.01% 532
2015
Q1 		$233K Hold
3,431
– – ﹤0.01% 484
2014
Q4 		$318K Buy
3,431
+885
+35% +$91.5K ﹤0.01% 453
2014
Q3 		$268K Buy
+2,546
New +$354K ﹤0.01% 463

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MDGL Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Madrigal Pharmaceuticals (MDGL) stake by 94% in Q2 2026, selling an estimated $13.4M and leaving 1,782 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MDGL in Q3 2014 and has held it in 30 quarters since. The position peaked at $39.3M in Q3 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 1,782 shares of Madrigal Pharmaceuticals worth $957K as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,155 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $13.4M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1208 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Madrigal Pharmaceuticals in Q3 2014 and has held it in 30 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Madrigal Pharmaceuticals position peaked at $39.3M in Q3 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.